Evaluate's Ask Ella Wins Enterprise AI Search Solution of the Year at 2026 AI Breakthrough Awards
核心洞察
Evaluate (搜索)'s AI-powered search tool Ask Ella (搜索) has been named "Enterprise AI Search Solution of the Year" in the 9th annual AI Breakthrough Awards program, recognizing innovation in pharmaceutical market intelligence.
Ask Ella (搜索), embedded in the Evaluate (搜索) Pharma platform, breaks down complex queries, reasons across proprietary data, and returns structured, traceable answers in seconds to accelerate strategic decision-making.
Norstella (搜索) CEO Mike Gallup highlighted that more than two dozen AI agents are already live, driving faster decisions across forecasting, trial design, market access, and patient activation.
Evaluate (搜索), a Norstella (搜索) company and leading global provider of market insights for the pharmaceutical industry, announced on June 25, 2026 that its AI-powered search tool, Ask Ella (搜索), has been named "Enterprise AI Search Solution of the Year" in the 9th annual AI Breakthrough Awards program. The awards, conducted by AI Breakthrough, recognize the top companies, technologies, and products in the global artificial intelligence market.
Embedded within the Evaluate (搜索) Pharma platform, Ask Ella (搜索) represents a significant departure from conventional search functionality. The tool autonomously breaks down complex questions into the appropriate sequence of queries, reasons across Evaluate's proprietary data, and returns structured, traceable answers in seconds — all without disrupting users' existing workflows. By synthesizing complex datasets into clear, actionable insights, Ask Ella enables users to understand market dynamics, competitor activity, and portfolio impact with unprecedented speed.
"This recognition affirms what we're building toward — a future where life sciences organizations can turn trusted data into critical decisions in seconds, not weeks," said Mike Gallup, CEO of Norstella (搜索). "With more than two dozen AI agents already live, and in production, Norstella is driving faster, more accurate decisions across forecasting, trial design, market access, and patient activation. When our clients move faster and smarter, the patients waiting for life-changing therapies are the ultimate beneficiaries."
The solution delivers measurable productivity improvements while maintaining the rigorous accuracy standards demanded by the pharmaceutical industry. Critically, Ask Ella (搜索) manages the complexity of navigating against complex datasets autonomously, leveraging what the company describes as the industry's most trusted data. This capability provides users with significant time savings, allowing them to redirect their focus toward strategic decision-making rather than manual data retrieval and analysis.
Suzanne Caruso, Clinical & Strategic Intelligence President of Norstella (搜索), positioned Ask Ella (搜索) as one component of a broader AI strategy. "Ask Ella is just part of our AI vision across all of our Norstella solutions," Caruso said. "Ask Ella is one proof point in a much larger shift in how our clients want to work within our solutions. Later this year we introduce our agentic platform built to harness, synthesize, and act on the most complex biopharma data in the industry."
The AI Breakthrough Awards have researched, analyzed, and recognized advances in artificial intelligence for nearly a decade. This year's program drew thousands of nominations from over 20 countries across categories including Agentic AI, Generative AI, Computer Vision, AIOps, Robotics, Natural Language Processing, and industry-specific AI applications — reflecting what organizers describe as the explosive global growth of AI and its emergence as the defining technology of the current era.
Norstella (搜索)'s portfolio of brands — including Citeline, Evaluate (搜索), MMIT, Panalgo, Skipta, and The Dedham Group — provides technology, data, and expert insights spanning the drug development lifecycle. The company's AI engine supports decision-making across forecasting, clinical trial design and regulatory strategy, market access, and patient activation, with the stated mission of smoothing the path to life-saving therapies for patients and providers.